

REVIEW

Open Access



Oxidative stress and ROS-mediated cellular events in RSV infection: potential protective roles of antioxidants

Xue Yang^{1†}, Xue Liu^{1†}, Yujun Nie¹, Fei Zhan¹ and Bin Zhu^{1*}

Abstract

Respiratory syncytial virus (RSV), a member of the Pneumoviridae family, can cause severe acute lower respiratory tract infection in infants, young children, immunocompromised individuals and elderly people. RSV is associated with an augmented innate immune response, enhanced secretion of inflammatory cytokines, and necrosis of infected cells. Oxidative stress, which is mainly characterized as an imbalance in the production of reactive oxygen species (ROS) and antioxidant responses, interacts with all the pathophysiologic processes above and is receiving increasing attention in RSV infection. A gradual accumulation of evidence indicates that ROS overproduction plays an important role in the pathogenesis of severe RSV infection and serves as a major factor in pulmonary inflammation and tissue damage. Thus, antioxidants seem to be an effective treatment for severe RSV infection. This article mainly reviews the information on oxidative stress and ROS-mediated cellular events during RSV infection for the first time.

Keywords Respiratory syncytial virus, Oxidative stress, Reactive oxygen species, Nrf2, NLRP3, NETs, HMGB1

Introduction

Respiratory syncytial virus (RSV), which belongs to Orthopneumovirus genus of the Pneumoviridae family, is a frequent pathogenic agent responsible for respiratory infections in infants, young children, the elderly and people with poor immune function [1–3]. The single-stranded RNA genome is enclosed in a lipoprotein envelope with major transmembrane proteins, including the viral attachment protein (G) and fusion protein (F) which contribute to the infection of host cells. RSV significantly disrupts the airway and alveolar epithelium and induces airway inflammation with neutrophil infiltration,

accumulation of mucus, cellular debris, and edema, leading to airway obstruction and turbulent gas flow [4]. Afterward, RSV infection may give rise to long-term sequelae such as repeated wheezing and asthma, which result in increased health care costs and reduced quality of life [3, 4]. In addition, since infection with RSV does not lead to long-term immunity, children and adults can suffer from recurrent respiratory infections. A recent systematic analysis revealed that RSV is a significant cause of morbidity and mortality in children aged 0 to 5 years around the world, particularly in the first six months of life and in low-income and middle-income countries [2]. Additionally, with more physical encounters brought on by the relaxation of COVID-19 restriction measures, RSV-related hospitalizations among children under the age of five can be anticipated to rise, potentially exceeding the numbers reported in prior RSV seasons [5]. The real-world disease burden caused by RSV makes it an urgent matter to develop effective antivirals and vaccines for RSV. Fortunately, recent advancements have been

[†]Xue Yang and Xue Liu contributed equally to this work and share first authorship

*Correspondence:

Bin Zhu
zhubin20sci@163.com

¹ Department of Pediatrics, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021, Hubei, China



made. RSV prefusion F protein-based (RSVpreF) vaccine (Abrysvo, Pfizer), RSVPreF3 vaccine (Arexvy, GSK), and mRNA-1345 (Moderna) have been approved by the US Food and Drug Administration (FDA) for the prevention of RSV infection in people over 60 years of age recently [6, 7]. Moreover, the first maternal RSVpreF vaccine (Abrysvo, Pfizer) was recently greenlit by the US FDA to prevent severe illness in infants from birth to 6 months [8]. Monoclonal antibody (mAb) prophylaxis is another prevention strategy against RSV infections in a small subset of very high-risk infants and young children, but is expensive for the low-middle income settings. Palivizumab, a monoclonal anti-RSV fusion protein, is the first antiviral mAb approved for RSV treatment. Even so, it is currently approved only for the prophylactic treatment of RSV in specific infants due to its high costs and limited effectiveness [9]. Nirsevimab is a novel long-acting mAb product intended for use in newborns and infants to protect against RSV disease that was approved by the FDA recently. But Nirsevimab's cost will still be a potential implementation barrier, particularly for ambulatory practices [10]. Therefore, it is necessary and pressing to develop affordable and effective interventions through a better understanding of cellular factors and signaling events that regulate RSV infection.

A clinical study determined that oxidative stress may contribute to the pathogenesis of RSV-induced acute bronchiolitis and correlate with the disease severity [11]. The definition of oxidative stress indicates “an imbalance between pro-oxidants and antioxidants with concomitant dysregulation of redox circuits and macromolecular damage” [12]. Oxidative stress is often recognized as a signaling mechanism for many cellular processes, including proliferation, differentiation, senescence, signaling, transcription factor activation, apoptosis, motility, and metabolism [13]. As pro-oxidants, reactive oxygen species (ROS) comprise superoxide anion (O_2^-), hydroxyl radical (HO^\bullet), hydrogen peroxide (H_2O_2), and some other reactive molecules and free radicals. Cellular ROS are attributed to mitochondrial oxidative metabolism or ROS-generating enzymes, mainly nicotinamide adenine dinucleotide phosphate oxidases (NADPH oxidases, NOX) and xanthine oxidase (XO). Antioxidant enzymes (AOEs) include superoxide dismutase 1 (SOD 1), SOD 2, SOD 3, catalase, glutathione peroxidase, and glutathione S-transferase, which can either directly decompose ROS or facilitate antioxidant reactions. Accumulated evidence has shown that ROS are essential intracellular second messengers that work in complex signaling networks and regulate various cellular signaling processes [14]. Many lines of evidence have shown that marked signs of increased production of ROS accompany multiple respiratory viral infections, including RSV, influenza A

viruses, Sendai virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and rhinovirus [15–19], and the serum level of O_2^- is a predictor of COVID-19 severity in patients [20]. ROS are known to contribute to the suppression of some respiratory infections through the induction of innate immune responses [21]. However, excessive ROS can induce cell death, which boosts the release and spread of virions and thus stimulates the replication of respiratory viruses with a lytic life cycle [22]. Furthermore, overproduction of ROS plays an important role in cellular events including Nod-like receptor protein (NLRP) 3 inflammasome activation, neutrophil extracellular trap (NET) and high-mobility group box 1 (HMGB1) release, DNA damage and acquired ciliopathies, which contribute to severe RSV disease. Thus, antioxidant treatments seem to be effective in ameliorating severe RSV infection [15].

RSV infections and ROS production, oxidative stress, viral replication, and the immune response are related. Therefore, this review mainly analyzes the key roles of ROS and information on the oxidative stress associated with the infections caused by RSV.

Sources of ROS in RSV-infected cells

NADPH oxidases, as ROS-generating enzymes, catalyze the production of the superoxide anion via one-electron transmembrane transfer to molecular oxygen. There are seven NADPH oxidase isoforms: NOX1–NOX5, DUOX1, and DUOX2 [23, 24]. These NADPH oxidase isoforms are expressed in different membranes depending on the cell type. They are distributed in the phagosome, mitochondria, endoplasmic reticulum, nucleus and plasma membrane for ROS production [25–27]. RSV can induce ROS generation by neutrophils, and pretreatment with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) abrogates this effect, indicating that RSV stimulates ROS generation through NADPH oxidase activation to a certain degree [28]. Among the NADPH oxidases, NOX2 is classically expressed in cells of the innate immune system, including neutrophils, monocytes, and macrophages [29–31]. Notably, NOX2 is expressed in epithelial cells to a lesser extent. ROS have been shown to act as a redox switch required for efficient RSV-mediated activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and interferon regulatory factor (IRF) 3 activation pathways [32, 33]. NOX2 has been identified as a specific source of ROS responsible for the oxidant-dependent activation of NF- κ B observed in RSV-infected human airway epithelial cells (hAECs) [34]. Induction of NOX1 in A549 cells during RSV infection also leads to the upregulation of ROS [35]. Further study is needed to identify the contribution of other

ROS-generating enzymes to ROS production in different kinds of cells.

Mitochondria are the main location of aerobic respiration to supply energy and other notable sources of ROS in cells [36, 37]. Generally, various viruses enhance the generation of mitochondrial ROS (mtROS), which activates certain host cellular pathways that facilitate viral replication [38–40]. This can also be confirmed in cells infected by RSV [41, 42]. RSV can induce microtubule/dynein-dependent mitochondrial perinuclear clustering and translocation toward the microtubule-organizing center, which is concomitant with impaired mitochondrial respiration, loss of mitochondrial membrane potential, and increased production of mtROS. Agents that target dynein/microtubules or inhibit mtROS production strongly reduce RSV production and lung inflammation, which indicates that RSV utilizes host cell mitochondria to boost mtROS production to facilitate virus replication [41]. Further study revealed that mitochondrial complex I activity is central to RSV infection. Reduced activity of complex I leads to impaired mitochondrial respiration, to increased mtROS generation and to enhanced virus production, which can be reversed by the mtROS scavenger mitoquinone mesylate (MitoQ) [43]. In addition, RSV induces endoplasmic reticulum (ER) stress and a non-canonical unfolded-protein response (UPR) [44], which triggers ER Ca^{2+} release and transport into mitochondria, leading to mitochondrial lumen Ca^{2+} (mt- Ca^{2+}) overloading [45]. As an increased level of mt- Ca^{2+} is a key factor for the production of mtROS [45], we infer that the RSV-induced ER stress/mt- Ca^{2+} /mtROS cascade is another pathway of mtROS production in RSV infection. Moreover, increased immune-responsive gene-1 (IRG1) induction in AECs and mouse lungs is responsible for ROS production during RSV infection [46]. IRG1 induction is described to enhance the production of ROS presumably through the promotion of the pentose phosphate pathway [47]. In contrast, itaconate, which is generated by IRG1 in the mitochondrial matrix, works as a fine activator of nuclear factor erythroid 2-related Factor 2 (Nrf2) [46, 48]. Thus, RSV-induced IRG1 generation seems to play a complicated role in oxidative stress.

Oxidative stress and enhanced ROS production during RSV infection

RSV infection is associated with increased production of ROS, degradation of Nrf2, and decreased expression of AOE in cells, mice, and children, leading to oxidative stress and lung damage (Fig. 1) [15, 49–53]. ROS are byproducts of cellular metabolism and can be either beneficial, at low levels, or harmful, at high levels, to the cell. However, in experimental animal or cell models of RSV infection, an increase in ROS levels and the existence of




Fig. 1 Oxidative stress and sources of ROS in RSV infection.

To the best of our knowledge, RSV-induced ROS production is partially attributed to NADPH oxidases/NOX, among which NOX1 and NOX2 are involved in ROS generation by epithelial cells. RSV can induce mitochondrial ROS (mtROS) via mitochondrial respiration damage and dysfunction. RSV can also promote Nrf2 deacetylation, ubiquitination, and degradation, leading to decreased expression of AOE. All of these cellular events result in an imbalance between pro-oxidants and antioxidants, leading to oxidative stress

oxidative stress have been demonstrated, and inhibiting ROS generation was shown to improve the disease, which indicates the unfavourable role that oxidative stress and ROS play in RSV infection [15, 28, 35, 46, 54]. Enhanced ROS production can be observed in the human airway epithelial cell lines BEAS-2B and A549 and in immune cells such as neutrophils and macrophages during RSV infection [15, 28, 35, 54].

Nrf2 is an important redox-responsive protein and the master regulator of the expression of AOE, which helps protect cells from oxidative stress and injury [55]. Under normal physiological conditions, most Nrf2 is sequestered in the cytoplasm by its covalently bound inhibitor Kelch-like ECH-associated protein 1 (Keap1) and cannot translocate into the nucleus [56–59]. Under oxidative stress, Nrf2 detaches from Keap1 and translocates to the nucleus, where it heterodimerizes with one of the small Maf (musculoaponeurotic fibrosarcoma oncogene homolog) proteins, which facilitates its binding to the antioxidant response elements (ARE) and activates ARE-dependent gene expression of a series of antioxidative, antidotal and cytoprotective proteins [57]. However, during infection, RSV induces ROS overproduction but Nrf2 deacetylation, ubiquitination, and degradation via the proteasome pathway both in vitro and in vivo, which leads to decreased expression of ARE [53,

60]. Upregulating the expression of Nrf2 and AOE can reduce RSV infection in human lung epithelial cells and mitigate RSV-induced injury and oxidative stress in mice [53, 61]. A recent study indicated that the H₂S donor GYY4137 decreases Keap1 levels and modulates pathways involved in RSV-induced Nrf2 degradation, contributing to the significantly increased Nrf2 levels and AOE gene expression, which could be explored as a potential therapeutic application in RSV infection [62].

ROS-mediated cellular events in RSV infection

ROS and NLRP3 inflammasome activation

As germline-encoded receptors in host cells, pattern recognition receptors (PRRs), which include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), and Nod-like receptors (NLRs), recognize and respond to diverse pathogen-associated molecular patterns (PAMPs)

and damage-associated molecular patterns (DAMPs) derived from invading viruses, thus becoming involved in the innate immune system [63]. PRRs can act as cytosolic PAMP and DAMP sensors and form the protein complexes known as inflammasomes, among which the NLRP3 inflammasome is the most well studied and plays a vital role in both inflammation and host antiviral immune responses. The three major components of the NLRP3 inflammasome are NLRP3, which captures the danger signals and recruits downstream molecules; procaspase-1, which elicits maturation of the cytokines interleukin (IL)-1 β and IL-18 and processing of gasdermin D to mediate cytokine release and pyroptosis; and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which functions as a bridge connecting NLRP3 and procaspase-1 [64]. Activation of the NLRP3 inflammasome requires two signals during viral infections (Fig. 2). The first is signal 1




Fig. 2 ROS-mediated NLRP3 inflammasome activation and lytic cell death in RSV-infected macrophages. Signal 1: Activation of the TLR/Myd88/NF- κ B pathway promotes the expression of NLRP3, pro-IL-1 β , and pro-IL-18. Signal 2: RSV-induced ROS overproduction and potassium (K⁺) efflux as well as mitochondrial dysfunction contribute to NLRP3 inflammasome activation, leading to caspase 1 activation, which induces the cleavage of pro-IL-1 β and pro-IL-18 into their mature and biologically active forms. Lytic cell death mechanisms: ASC-NLRP3 inflammasome-dependent caspase-1 activation promotes pyroptotic cell death and may also partially contribute to activation of the necroptosis pathway in RSV-infected macrophages during RSV infection. The RIPK3/MLKL pathway plays a positive regulatory role in necroptosis. The pivotal role of ROS in promoting lytic cell death in RSV-infected macrophages is also highlighted

(priming signal); the activation of PRRs, tumor necrosis factor receptors (TNFRs), or interferon receptors (IFNRs) induces NF- κ B activation and triggers the transcription of NLRP3, pro-caspase-1, pro-IL-1 β , and pro-IL-18. The second is signal 2 (activation signal); multiple DAMPs and PAMPs induce NLRP3 inflammasome assembly and activation [65]. Currently, NLRP3 stimuli have been demonstrated to induce multiple molecular and cellular signaling events, including ionic flux, mitochondrial dysfunction, the generation of ROS (especially mtROS), and lysosomal damage, leading to the activation of the NLRP3 inflammasome [66, 67]. Among the “second signals”, the ROS model represents a common pathway underlying NLRP3 inflammasome activation [68] since ROS are at the crossroads of inflammasome and inflammation [69]. Overproduction of ROS is reported to be essential and is involved in diverse signal axes for NLRP3 inflammasome activation [70–72]. ROS-thioredoxin-interacting protein (TXNIP)-NLRP3 axis activation is responsible for various pathogen-induced organ or tissue injuries [73–75]. Moreover, ROS can activate NLRP3 by inducing Ca²⁺ influx through transient receptor potential melastatin 2 (TRPM2) channels [73]. ROS can also serve as an important inflammasome-activating signal and activate inflammasomes through mitogen-activated protein kinases (MAPK) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) [69]. Furthermore, NLRP3 inflammasome-driven inflammation recruits inflammatory cells like neutrophils and macrophages, which in turn produce ROS, indicating a feedback loop between ROS and NLRP3 inflammasome [67].

Many lines of evidence suggest that RSV can activate the NLRP3 inflammasome and induce inflammasome-related airway inflammation, even pyroptosis [70, 76, 77], similar to other RNA viruses [73]. As we mentioned before, RSV can induce excessive production of ROS [15, 54], which contributes to the activation of the NLRP3 inflammasome in RSV infection (Fig. 2) [70, 78]. An earlier cell study illustrated that the priming signal is exerted by activation of the TLR2/myeloid differentiation primary response 88 (MyD88)/NF- κ B pathway, which is required for pro-IL-1 β and NLRP3 gene expression during RSV infection [78]. In fact, except for TLR3, all TLRs recruit MyD88 to their receptor complex, as do members of the IL-1 receptor family. MyD88 recruits interleukin-1 receptor-associated kinase 1 (IRAK1), IRAK4, and then TNF receptor-associated Factor 6 (TRAF6), which results in the activation of NF- κ B [79]. Afterward, as “second signals”, intracellular ROS and potassium (K⁺) efflux due to stimulation of ATP-sensitive ion channels are involved in triggering inflammasome activation [78], leading to caspase 1 activation and turning pro-IL-1 β and pro-IL-18 into their mature and biologically active forms [78, 80].

Lytic cell death is an inflammatory cell death caused primarily by three distinct cellular mechanisms: pyroptosis, necroptosis, and ferroptosis [81–83]. Since intracellular constituents released from dying cells are among the stimuli that trigger proinflammatory gene expression programs in innate immune cells, inhibition of cell death may work as a potential therapeutic strategy for excessive or chronic inflammation [84]. A recent study revealed that RSV induces lytic cell death mechanisms in macrophages, specifically through ASC-NLRP3 inflammasome activation of both caspase-1-dependent pyroptosis and receptor-interacting serine/threonine-protein kinase 3 (RIPK3), as well as mixed lineage kinase domain-like pseudokinase (MLKL)-dependent necroptosis [70]. The ASC-NLRP3 inflammasome may also partially contribute to the activation of the necroptosis pathway during RSV infection [70]. A critical role of ROS is underlined in positively regulating lytic cell death of RSV-infected macrophages, and inhibition of ROS by DPI, a potent ROS inhibitor, would dampen lytic cell death [70]. Moreover, NLRP3 inflammasome activation by mtROS plays a significant role in pathogenesis of exaggerated inflammation and targeting mtROS-NLRP3 inflammasome axis may be a promising strategy for alleviating lung injury and treating acute lung injury (ALI) /acute respiratory distress syndrome (ARDS) [85].

Although the NLRP3 inflammasome is a key player in antiviral responses [65], it also leads to an excessive innate immune response, which is implicated in RSV-induced lung inflammation and damage. Multiple interventions and treatments have been reported to attenuate and inhibit the activation of the NLRP3 inflammasome during RSV infection, which abrogates lung inflammatory injury and long-term airway disease development [76, 77, 80, 86]. Thus, it is plausible to infer that inhibiting ROS production may serve as a potential measure to prevent ROS-mediated NLRP3 inflammasome activation and lytic cell death, which may ameliorate RSV-induced lung inflammatory damage. However, the effect of inhibiting ROS-mediated NLRP3 inflammasome activation on RSV replication remains unclear. Further study is still needed.

ROS and NET release

In addition to the traditional antimicrobial mechanisms of phagocytosis, ROS production, and degranulation, neutrophils can also fabricate NETs, which are important structures comprising a web-like deoxyribonucleic acid (DNA) backbone coated with antimicrobial proteins, such as histones, neutrophil elastase (NE), myeloperoxidase (MPO), and α -defensins, to prevent the spread of infectious virions [87]. NETs arise from the release of granular and nuclear contents of neutrophils in the

extracellular space in response to microorganisms, soluble factors, and host molecules. NETosis is a unique and dynamic cell death program for neutrophils that is responsible for NET formation [88]. The specific cell components and signaling cascades required for NETosis to release these DNA threads may vary depending on the stimulus [89]. Delgado-Rizo has reviewed three models for NETosis: ROS-dependent suicidal NETosis, ROS-dependent vital NETosis, and ROS-independent vital NETosis (reviewed in [90]). Suicidal NETosis, mainly with a duration of 2–4 h, is the principal and best-described model for NET release [91, 92], even though the molecular mechanisms are still not well understood [93]. Once activated through the recognition of stimuli, neutrophils begin to package and activate the NADPH oxidase complex through protein kinase C (PKC)/Raf/MERK/ERK to promote ROS production, which acts as a second messenger in suicidal NETosis by promoting the gradual separation and loss of the nuclear membrane and peptidyl arginase deaminase 4 (PAD4)-mediated histone citrullination, allowing for chromatin decondensation [90, 94]. Increased cytosolic Ca^{2+} also serves as a cofactor for PAD4, which promotes the deamination of histones and allows the decondensation of chromatin, contributing to nuclear DNA release and suicidal NETosis [95]. In vital NETosis, neutrophils release NETs without exhibiting a loss of nuclear or plasma membrane within 5–60 min, and it occurs independently of ROS and the Raf/MERK/ERK pathway [90]. Finally, another type of vital NETosis dependent on ROS has been described, in which mitochondrial DNA is released instead of nuclear DNA [96].

During RSV infection, an innate immune response characterized by the release of chemokines and cytokines is activated, which promotes neutrophil influx into the respiratory tract [97–99]. The influx of neutrophils to the lungs is associated with increased airway mucus production, cellular inflammation, ROS production, NETosis, and heightened lung damage [100]. Neutrophil-endothelial interactions in RSV bronchiolitis seem to be with a potential for prediction of severity of disease [99]. RSV particles and RSV F protein are both reported to induce NET formation by human neutrophils (Fig. 3). Moreover, RSV F protein is capable of stimulating NET release in a manner dependent on TLR-4 activation, potent NADPH oxidase-derived ROS production, and ERK and p38 MAPK phosphorylation [101]. The enzyme PAD-4-mediated histone citrullination is known to be crucial to chromatin decondensation during NETosis [89]. RSV is able to induce classical ROS-dependent NET release through PAD-4 and necroptosis pathway activation, which is also dependent on the phosphatidylinositol 3-kinase (PI3K)/AKT, ERK, and p38 MAPK pathways. Likewise, RIPK1,




Fig. 3 ROS-dependent NET release and NETosis by RSV-infected neutrophils. RSV F glycoprotein stimulates TLR4 which may activate the Raf/MEK/ERK pathway and subsequent NADPH oxidase complexes, leading to ROS production. ROS can promote the separation and loss of the nuclear membrane and activate PAD4-mediated histone citrullination to allow chromatin decondensation. RIPK1/RIPK3/MLKL induces cytomembrane rupture and contributes to NETosis. PI3K/AKT and p38 MAPK are also involved in NETosis, although the mechanism is not fully understood

RIPK3, and MLKL are essential to RSV-induced NETosis as well, among which MLKL, the necroptosis executioner protein, is likely to promote membrane-disrupting pores leading to neutrophil lysis and NET extrusion. In addition, neutrophils can be stimulated by RSV-infected alveolar epithelial cells or lung fibroblasts and release NETs in a virus replication- and concentration-dependent manner [28]. RSV triggers the formation of NE and MPO, which have also been shown to modulate NET release [102].

The NET formation has been widely demonstrated as an effective mechanism to prevent microbial dissemination and avoid uncontrolled infections. For instance, the presence of NETs decreases RSV-induced cellular damage, possibly by directly affecting viral particle capture and/or interfering with the fusion activity of the F protein [103]. However, NETs are supposed to be a double-edged sword, and excessive NET formation has been described in many human diseases, infectious and noninfectious [104]. For example, excessive NET formation is implicated in the pathogenesis of ventilator-induced lung injury [105], and NETs are also identified as a key marker of disease severity and treatment response in bronchiectasis [106]. Furthermore, although NETs are able to capture RSV and exhibit a potential antiviral effect, they aggravate the immune response of the infection and cause airway obstruction in infants with severe RSV-LRTI [107]. Calves with severe

bovine RSV infection also suffer from an extensive release of NETs, which causes airway obstruction [107, 108]. Since NETs are decorated with NE, MPO, and granule proteins, they can induce pathogen-induced lung injury and inflammation [109, 110]. Moreover, the overactivated ROS-NET pathway plays a role in an extensive microthrombus formation with multiorgan failure in systemic viral infection [111], which indicates the harmful effects of excessive NET formation. Treatment with DPI can significantly inhibit F protein-induced NET production in RSV-infected neutrophils [101], and inhibition of ROS production can decrease NET formation, cellular inflammation, mucus hypersecretion and diminish the severity of viral bronchiolitis in mice [100]. These results indicate that RSV tends to induce ROS-dependent suicidal NETosis. Targeting the overproduction of ROS may regulate NET formation and attenuate lung damage and inflammation in severe respiratory virus infection such as RSV. To date, as most researchers consider the adverse side effects of excessive NETs, reducing the formation and release of NETs has received increasing attention. Another strategy to modulate the neutrophil response and NET release is the ligation of inhibitory receptors, also known as immune checkpoints [112, 113]. Through a study of fresh neutrophils from the airways of a large cohort of infants with life-threatening RSV infection and controls, two immune checkpoints, signal inhibitory receptor on leukocytes (SIRL)-1 and leukocyte-associated immunoglobulin-like receptor (LAIR)-1, were found to regulate neutrophil function, inhibit NET formation by sputum neutrophils of RSV patients and modulate the course of severe RSV bronchiolitis in a positive way [113]. Collectively, excessive NETs are considered to do more harm than good in severe RSV infection. Inhibition of overproduction of ROS to reduce the release of NETs seems to be a potential strategy to improve the severe RSV diseases.

ROS and HMGB1 release

HMGB1 is a ubiquitous redox-sensitive chromatin-binding protein that can be released into the extracellular space to function as a proinflammatory cytokine. As an alarmin protein, HMGB1 is involved in human host defense and immune surveillance by alerting the immune system to infectious and tissue damage signals and triggering an immediate response. However, when misregulated, HMGB1 can become deleterious and induce serious cell and tissue damage [114], which is involved in many pathological conditions, including systemic lupus erythematosus, colorectal cancer, ischemia/reperfusion injury, and type 2 diabetes [115–118]. Several cellular mechanisms, such as vesicular transport, inflammasome activation, ROS generation, and necroptosis, are known to regulate HMGB1 release [97, 119–121].

RSV infection is reported to promote HMGB1 release by AECs [97, 121]. Increased levels of HMGB1 have also been observed in the lungs of RSV-infected rat pups, peripheral blood, and nasopharyngeal aspirates in infants with RSV bronchiolitis [122–124]. Interestingly, an upregulation of the receptor for advanced glycation end products (RAGE) and HMGB1 is also found among patients with the most severe forms of COVID-19 [125], which indicates the harmful effects of augmented HMGB1 in respiratory viral infections. A study of subcellular localization indicated that RSV infection results in an overall decline in cellular HMGB1 protein levels but an enhanced translocation of HMGB1 from the nucleus to the cytoplasm and the final release into the extracellular space [121]. Oxidative stress is reported to trigger the translocation of HMGB1 from the nucleus to the extracellular space [126, 127], and antioxidants are reported to be protective in the setting of experimental infection/sepsis and injury, including ischemia–reperfusion, partly by attenuating HMGB1 release and systemic accumulation [128]. RSV-induced ROS generation has been demonstrated to promote the release of HMGB1 from cells, and treatment with ROS scavengers has been shown to significantly inhibit HMGB1 release [121]. HMGB1 release is thought to be ROS-dependent in RSV infection. Moreover, there is another cellular event involved in HMGB1 release during RSV infection. RSV-induced epithelial cell necroptosis, characterized by increased phosphorylated RIPK1 and phosphorylated MLKL but not active caspase-3 expression, coincides with AEC sloughing, HMGB1 release, and neutrophilic inflammation [97]. Since ROS overproduction is implicated in positively regulating necroptosis of RSV-infected macrophages via the RIPK3/MLKL pathway [70], there is reason to deduce that RSV-induced ROS may also contribute to AEC necroptosis, which promotes the release of HMGB1. A recent study revealed that RSV infection of hAECs induces the biphasic release of HMGB1 at 6 (“early”) and 24 (“late”) hours post-infection (Fig. 4). The early phase of HMGB1 release at 6 h post-infection, which is cell death-independent but MLKL dependent, promotes the late phase of HMGB1 release via the activation of RAGE, initiation of a second wave of RIPK1/RIPK3/MLKL phosphorylation and occurs with cell necroptosis [129]. The TLR4/NF- κ B pathway has also been confirmed to be involved in RSV-induced HMGB1 release from AECs [130]. As ROS regulate mitogen- and stress-activated protein kinase 1 (MSK1), a kinase upstream of phospho-Ser-276 formation required for RSV-induced RelA/NF- κ B activation [32], it is plausible that ROS also regulate HMGB1 release through NF- κ B signaling. Further research is needed to test these hypotheses.




Fig. 4 ROS-mediated HMGB1 release by AECs and HMGB1-induced excessive inflammatory response in RSV infection. RSV infection of AECs induces the biphasic release of HMGB1: early phase, which is necroptosis-independent but MLKL dependent, and late phase, which is necroptosis dependent. The early phase of HMGB1 release promotes the late phase of HMGB1 release via the activation of RAGE and initiation of RIPK1/RIPK3/MLKL phosphorylation. The TLR4/NF-κB pathway is also involved in HMGB1 release from AECs. RSV-induced ROS generation promoting the release of HMGB1 from cells likely occurs through the RIPK1/RIPK3/MLKL pathway and MSK1/NF-κB pathway. The release of HMGB1 induces an excessive inflammatory response that contributes to RSV pathogenesis

AEC necroptosis-induced HMGB1 release is reported to be associated with increased viral load, augmented type 2 inflammation, and airway remodeling in RSV infection, and intervention to inhibit cell necroptosis can attenuate these pathologies [97]. Once activated, Group 2 innate lymphoid cells (ILC2s), which are the innate counterparts of T-helper type 2 (Th2) cells, act as potent promoters of airway inflammation and hyperresponsiveness in RSV bronchiolitis and childhood wheezing/asthma [131]. RSV-induced HMGB1 and other epithelial-derived alarmin proteins, including IL-33, IL-25, and thymic stromal lymphopoietin (TSLP), promote ILC2 activation, which leads to the induction of a type 2 response and the production of type 2 cytokines [132]. HMGB1 is mainly dependent on TLR 2, TLR 4, and RAGE to trigger intracellular MAPK and NF-κB signal transduction, and mediate innate and adoptive immune responses. It also mediates the Th2 inflammatory response with the participation of TLR3, TLR9, T-cell immunoglobulin mucin (TIM) 3, CD24, and antiN-methyl-D-aspartate receptor (NMDAR) in asthma [133]. RSV infection promotes necroptosis and HMGB1 release by AECs, which can facilitate the secretion of proinflammatory mediators and

the activation of the NF-κB and P38 MAPK pathways in immune cells in a paracrine mechanism, thus promoting the inflammatory response that contributes to RSV bronchiolitis pathogenesis [97, 130]. Clinical studies have revealed that higher levels of HMGB1 correlate with the clinical severity of RSV-induced bronchiolitis [123] and act as an independent risk factor for children to develop asthma during follow-up [124]. Anti-HMGB1 mitigates both early-life viral disease and later-life asthma-like features [134]. Collectively, these results indicate that RSV-induced HMGB1 release enhances the type 2 response and the secretion of proinflammatory mediators and is associated with an elevated viral load, airway smooth muscle remodeling, and a higher risk of asthma. Therefore, blocking the proinflammatory function of HMGB1 may be an effective approach for developing novel therapeutics for RSV infection.

ROS and DNA damage

ROS are toxic but also act as signaling factors, directly or via oxidative modifications to cellular macromolecules such as lipids, proteins, and DNA. ROS can induce DNA damage, which includes base oxidation, abasic sites, and

even both single- and double-stranded DNA breaks [135, 136]. DNA double-strand breaks (DSBs) are the most dangerous type of DNA damage because they can activate DNA damage response (DDR) kinases, leading to initiation of DDR and loss of large chromosomal regions and influencing various types of DNA metabolism, especially replication and transcription. If DSBs are induced near or in transcription sites, transcription is repressed under ataxia telangiectasia mutated kinase (ATM) or DNA-dependent protein kinase catalytic subunit (DNA-PKcs) signaling [137, 138]. Programmed DNA single- or double-strand breaks seem to have a strategic role in the regulation of gene expression through the relief of DNA torsional stress and activation of promoters and enhancers [139].

The production of ROS in cells is considered one of the most important sources of DSBs, and endogenous ROS are also able to induce the conversion of single-stranded DNA lesions into double-stranded DNA breaks [140]. Persistent DNA damage signaling triggers

senescence-associated inflammatory cytokine secretion [141]. A study has shown that the production of RSV-induced mtROS results in the expression of DNA damage markers, such as phosphorylated tumor suppressor p53 (TP53), ATM, cyclin-dependent kinase inhibitor 1A (CDKN1A) and γ H2AFX (H2A histone family member X, phosphorylated on Ser 139), and proliferation arrest in cultured cells (Fig. 5) [42]. ATM, as a nuclear ROS and DNA damage sensor, is activated by RSV replication and translocated from the nucleus into the cytosol. In addition, the ATM-MSK1-phospho-Ser276 RelA-IRF7- RIG-I amplification loop plays a significant role in the innate immune response to paramyxovirus virus infections, including RSV and SeV (Fig. 5) [142]. γ H2AFX, a biomarker of DNA damage and aging, and tumor suppressor p53-binding protein 1 (TP53BP1), both of which are contained in DNA damage foci, indicate the existence of DSBs, the most dangerous type of DNA damage. Moreover, DSBs are associated with the accumulation of senescent cells, displaying all the hallmarks of the senescence




Fig. 5 ROS-mediated DNA damage and ATM-MSK1-phospho-Ser276 RelA-IRF7-RIG-I pathway in RSV-infected cells. ROS production induces DSBs and 8-oxo(d)Gua along with enrichment of enzymatically disabled OGG1 in RSV-infected cells. DSBs are associated with senescence, while OGG1 promotes the DNA occupancy of NF-κB and contributes to the augmented innate immune response. Moreover, NAC is able to reverse DSBs via the inhibition of ROS production. ATM, as a nuclear ROS and DNA damage sensor, is translocated from the nucleus into the cytosol and activates the MSK1-phospho-Ser276 RelA-IRF7-RIG-I amplification loop in RSV infection

phenotype in both mononuclear cells and syncytia [42]. RSV-induced senescence may be seen as a host defense mechanism, instructing “damaged” cells to cease proliferation. However, excessive accumulation of senescent cells may negatively affect their homeostasis because they can secrete massive amounts of factors to modulate cell growth, create a proinflammatory microenvironment or remodel the extracellular matrix [143, 144]. Thus, RSV-induced senescence may enhance airway tissue remodeling (exhibited by a loss of ciliated cells and an increase in secretory cells), potentially leading to permanent tissue damage and fibrosis [144]. The overall impact of cellular senescence on acute respiratory viruses may depend on host resilience factors [144]. Antioxidant therapy such as N-acetylcysteine (NAC) or reduced glutathione ethyl ester (GSHee) has been shown to be able to reverse DSBs [42], which may act as a protective measure to improve the pathological condition.

Generally, 7,8-dihydro-8-oxo(d)guanine (8-oxo(d)Gua) is one of the most abundant ROS-induced DNA lesions. It is removed through DNA base excision pathways by base-specific DNA repair enzymes, primarily by 8-oxoguanine DNA glycosylase 1 (OGG1) [145]. A recent study revealed that RSV infection increases the production of ROS and intrahelical 8-oxo(d)Gua primarily in transcription start site adjacent promoter sequences along with enrichment of enzymatically disabled OGG1 (Fig. 5). Since OGG1 couples RelA/NF- κ B to the expression of innate immune response genes in RSV-infected lungs and cells, these interactions lead to the expression of cytokines and chemokines, prominent lung inflammation, histological changes, and body weight loss in experimental animals. Pharmacological inhibition of OGG1 significantly decreases the innate immune response and reverses the situation. This study identifies the unprecedented role of ROS-induced DNA base lesions and cognate repair proteins as determinants of RSV-induced dysregulated inflammation. Pharmaceutical inhibition of the OGG1 interaction with 8-oxo(d)Gua is expected to have clinical utility against RSV-induced excessive lung inflammation [146]. Collectively, RSV-induced ROS play an important role in DNA damage, including DNA base lesions and DSBs, which are associated with cell senescence and excessive innate immune responses.

ROS and acquired ciliopathies

Functional motile cilia on airway cells, which serve as a necessary defense system, are critical for clearance of mucus-trapped particles and microorganisms out of the respiratory tract. Cilia contain or are quite similar to oxidant-generating systems such as nitric oxide synthases (NOS) or NADPH oxidases and mitochondria,

respectively [147, 148]. Motile cilia are rich in thiol-dense and thiol-regulatory proteins that are sensitive to the local redox environment [149, 150]. Dynein ATPases drive ciliary motility and are sensitive to the local redox microenvironment in each cilium. PKA, PKC, and protein phosphatase 1, which are located in cilia and regulate cilia motility, are also redox-sensitive [147, 149–151]. Therefore, redox balance is implicated as a potential modulator of cilia motility.

Analyses of ciliated cells show the specificity and tropism of RSV, which can induce oxidative stress [35, 152, 153]. The RSV G protein CX3C motif is capable of binding to human CX3CR1, which has been demonstrated to exist on the apical surface of ciliated human AECs [154, 155]. Through engagement with CX3CR1, G protein is reported to facilitate attachment and viral penetration into the host cell that results in nucleolin expression as well as suppression of gene transcripts specific to ciliated cells, which is coincident with the decreases in ciliated cells [155, 156]. However, another study has shown a different outcome. In this study, RNA sequencing (RNA-seq) was performed in nasal scrape biopsies obtained from infants admitted to the pediatric intensive care unit with critical RSV bronchiolitis requiring invasive or non-invasive respiratory support. The results revealed that increased expression of ciliated cell genes and estimated ciliated cell abundance positively correlate with the duration of hospitalization in infants with critical bronchiolitis [157]. One possible explanation of the discrepancy may be the different cell sources and distinguishing severity of RSV infection. The presence of the F protein in the cilia is also reported to contribute to cellular changes in the cilia and reduced cilia function [158]. Increased ciliary dyskinesia combined with ciliary loss and epithelial damage is an early feature of RSV infection, which is likely to result in reduced mucociliary clearance. Neither reduced ciliary beat frequency (CBF) nor reduced motile ciliated cells but rather an increased number of cilia with an abnormal beat pattern were observed in RSV-infected human ciliated nasal epithelial cells [153]. However, another study reported that RSV infection decreases CBF and affects mucociliary clearance at 4 days post infection [159]. A recent study has shown that RSV infection blocks cilia beating from day four, while human metapneumovirus infection does not affect cilia beating [160]. All of these results suggest that RSV infection affects the expression of ciliated cell genes, the number of cilia, ciliary dyskinesia and ciliary loss.

Mata et al. reported that RSV-induced H₂O₂ plays a significant role in cilia loss and dysfunction. Preincubation with NAC improves the situation by decreasing H₂O₂ generation and promoting the expression of GSH,




Fig. 6 ROS-mediated acquired ciliopathies and barrier dysfunctions in RSV infection. RSV-induced ROS are thought to play a significant role in cilia loss and dysfunction as well as AJC disruption, which result in epithelial barrier dysfunction and can be blocked by NAC or RNO by reducing ROS production

Nrf2 and heme oxygenase 1 (HO-1), which enhances the antioxidant effect, reverses the RSV-induced loss of ciliogenesis and decreases ciliary activity in an in vitro model of RSV infection in human bronchial epithelial cells [161]. Roflumilast N-oxide (RNO), a phosphodiesterase 4 (PDE4) inhibitor, also restores cilia motility and reverses a loss in cilia following RSV infection in human bronchial epithelial cells. In this process, RNO has been demonstrated to support the antioxidative apparatus compromised in RSV-infected cells and reduce ROS [162]. In addition, excessive production of RSV-induced ROS results in barrier dysfunction, which is characterized by apical junctional complex (AJC) disruption and can be exaggerated by titanium dioxide nanoparticles (TiO₂-NPs) and reversed by antioxidants [163]. The effects of these interventions indicate that ROS and oxidative stress

may contribute to “acquired ciliopathies” and barrier dysfunctions, and antioxidative treatment may be a potential measure to improve the situation (Fig. 6) [150].

Conclusions

The redox balance between pro-oxidants and antioxidants might directly or indirectly affect the progression and outcome of viral infections [164]. In this review, we emphasized the oxidative stress and ROS-mediated cellular events in RSV infection. Although proper ROS production serves as a beneficial host defense response, RSV-induced ROS overproduction plays an important role in many cellular events, including the elevated release of HMGB1 and NETs, the activation of NETosis and the NLRP3 inflammasome, increased DNA damage, “acquired ciliopathies” and barrier damage. Most of these ROS-mediated cellular events seem to do more harm than good in RSV infection. Substantial evidence has shown the beneficial effects of antioxidant treatment in severe RSV infection, such as inhibition of RSV replication and improvement of barrier dysfunction and lung inflammatory injury [15, 50, 62, 163, 165]. In addition, zinc is a stable divalent cation and does not directly undergo redox reactions, but it is involved in regulating the oxidant/antioxidant balance [166]. During RSV infection in A549 cells, both zinc depletion and the addition of exogenous ROS are beneficial for virus replication, while adding zinc blocks replication. Zinc chelation leads to ROS induction, whereas the addition of zinc blocks ROS induction [35]. All of these results indicate antioxidant treatment as a promising and novel approach to ameliorate RSV-induced acute lung inflammation and potentially prevent long-term consequences associated with RSV infection. However, there is still a pressing need to further characterize pathways, including those generated by oxidative stress, to prove the effect of antioxidant treatment and determine more effective therapeutic measures to improve the outcome of RSV infection (Table 1).

Table 1 The ROS-mediated cellular events and related main adverse effects in severe RSV infection

The ROS-mediated cellular events	The main adverse effects
NLRP3 inflammasome activation	Excessive innate immune responses and lung inflammatory injury
NET release	Airway obstruction, mucus hypersecretion, and heightened lung damage
HMGB1 release	Increased viral load, augmented type 2 inflammation, and airway remodeling
DNA damage	Excessive innate immune responses, cell senescence, and airway tissue remodeling
Acquired ciliopathies	Barrier dysfunctions and reduced mucociliary clearance

Abbreviations

AJC	Apical junctional complex
ALI	Acute lung injury
AOEs	Antioxidant enzymes
ARDS	Acute respiratory distress syndrome
AREs	Antioxidant response elements
ASC	Apoptosis-associated speck-like protein containing a caspase recruitment domain
ATM	Ataxia telangiectasia mutated kinase
CBF	Ciliary beat frequency
CDKN1A	Cyclin-dependent kinase inhibitor 1A
CLRs	C-type lectin receptors
DAMPs	Damage-associated molecular patterns
DDR	DNA damage response
DNA	Deoxyribonucleic acid
DPI	Diphenyleneiodonium
DSBs	Double-strand breaks
ER	Endoplasmic reticulum
ERK1/2	Extracellular signal-regulated protein kinases 1 and 2
F	Fusion protein
FDA	Food and Drug Administration
G	Attachment protein
GSHee	Glutathione ethyl ester
H2O2	Hydrogen peroxide
hAECs	Human airway epithelial cells
HMGB1	High-mobility group box 1
HO [•]	Hydroxyl radical
HO-1	Hemeoxygenase 1
IFNRs	Interferon receptors
ILC2	Group 2 innate lymphoid cells
IRAK1	Interleukin-1 receptor-associated kinase 1
IRF	Interferon regulatory factor
IRG1	Immune-responsive gene-1
Keap1	Kelch-like ECH-associated protein 1
LAIR	Leukocyte-associated immunoglobulin-like receptor
LRTI	Lower respiratory tract infection
mAb	Monoclonal antibody
Maf	Musculoaponeurotic fibrosarcoma oncogene homolog
MAPK	Mitogen-activated protein kinases
MitoQ	Mitoquinone mesylate
MLKL	Mixed lineage kinase domain-like pseudokinase
MPO	Myeloperoxidase
MSK1	Mitogen- and stress-activated protein kinase 1
mt-Ca ²⁺	Mitochondrial lumen Ca ²⁺
mtROS	Mitochondrial ROS
MyD88	Myeloid differentiation primary response 88
NAC	N-Acetylcysteine
NADPH Oxidases/NOX	Nicotinamide adenine dinucleotide phosphate oxidases
NE	Neutrophil elastase
NET	Neutrophil extracellular trap
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NLRs	Nod-like receptors
NLRP	Nod-like receptor protein
NMDAR	N-Methyl-D-aspartate receptor
NOS	Nitric oxide synthase
Nrf2	Nuclear factor erythroid 2-related factor 2
O ₂ ^{•−}	Superoxide anion
OGG1	8-Oxoguanine DNA glycosylase1
PAD4	Peptidyl arginase deaminase 4
PAMPs	Pathogen-associated molecular patterns
PDE4	Phosphodiesterase 4
PI3K	Phosphatidylinositol 3-kinase
PKC	Protein kinase C
IL	Interleukin
PRRs	Pattern recognition receptors
RAGE	Receptor for advanced glycation end products
RIG-I	Retinoic acid-inducible gene-I

RIPK3	Receptor-interacting serine/threonine-protein kinase 3
RLRs	RLG-I-like receptors
RNO	Roflumilast N-oxide
ROS	Reactive oxygen species
RSV	Respiratory syncytial virus
RSVpref	RSV prefusion F protein-based
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SIRL	Signal inhibitory receptor on leukocytes
SOD 1	Superoxide dismutase 1
Th2	T helper type 2
TIM 3	T-cell immunoglobulin mucin 3
TiO2-NP	Titanium dioxide nanoparticles
TLRs	Toll-like receptors
TNFRs	Tumor necrosis factor receptors
TP53	Tumor suppressor p53
TP53BP1	Tumor suppressor p53-binding protein 1
TRAF6	TNF receptor-associated factor 6
TRPM2	Transient receptor potential melastatin 2
TSLP	Thymic stromal lymphopoietin
TXNIP	Thioredoxin-interacting protein
UPR	Unfolded-protein response
XO	Xanthine oxidase
γH2AFX	H2A histone family member X, phosphorylated on ser 139
8-oxo(d)guanine	8-Oxo(d)Gua

Acknowledgements

The authors thank all participants in the study.

Author contributions

XY and XL conceived the study, participated in drafting the paper, gathering the articles, and revising the manuscript's linguistics. BZ guided the writing and editing of the article. YJN and FZ prepared figures and collected the references. The article's submission was reviewed and approved by all authors.

Funding

This review received no external funding.

Availability of data and materials

Not applicable.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Received: 4 July 2023 Accepted: 27 September 2023

Published online: 05 October 2023

References

- Barbati F, Moriondo M, Pisano L, et al. Epidemiology of respiratory syncytial virus-related hospitalization over a 5-year period in Italy: evaluation of seasonality and age distribution before vaccine introduction. *Vaccines* (Basel). 2020;8(1):15. <https://doi.org/10.3390/vaccines8010015>.
- Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022;399(10340):2047–64. [https://doi.org/10.1016/S0140-6736\(22\)00478-0](https://doi.org/10.1016/S0140-6736(22)00478-0).

3. Chatterjee A, Mavunda K, Krilov LR. Current state of respiratory syncytial virus disease and management. *Infect Dis Ther*. 2021;10(Suppl 1):5–16. <https://doi.org/10.1007/s40121-020-00387-2>.
4. Mammass IN, Drysdale SB, Rath B, et al. Update on current views and advances on RSV infection (Review). *Int J Mol Med*. 2020;46(2):509–20. <https://doi.org/10.3892/ijmm.2020.4641>.
5. Noble M, Khan RA, Walker B, Bennett E, Gent N. Respiratory syncytial virus-associated hospitalisation in children aged ≤ 5 years: a scoping review of literature from 2009 to 2021. *ERJ Open Res*. 2022;8(2):00593–2021. <https://doi.org/10.1183/23120541.00593-2021>.
6. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(29):793–801. <https://doi.org/10.15585/mmwr.mm7229a4>.
7. Qiu X, Xu S, Lu Y, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). *Cytokine Growth Factor Rev*. 2022;68:37–53. <https://doi.org/10.1016/j.cytogfr.2022.10.001>.
8. Harris E. FDA approves maternal RSV vaccine. *JAMA*. 2023. <https://doi.org/10.1001/jama.2023.16106>.
9. Lin YJ, Chung CH, Chi H, Lin CH. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study. *Pediatr Res*. 2019;86(5):628–34. <https://doi.org/10.1038/s41390-019-0492-7>.
10. O'Leary ST, Yonts AB, Gaviria-Agudelo C, Summer 2023 ACIP Update, et al. ACIP update: RSV prevention and updated recommendations on other vaccines. *Pediatrics*. 2023. <https://doi.org/10.1542/peds.2023-063955>.
11. Moreno-Solís G, Dela Torre-Aguilar MJ, Torres-Borrego J, et al. Oxidative stress and inflammatory plasma biomarkers in respiratory syncytial virus bronchiolitis. *Clin Respir J*. 2017;11(6):839–46. <https://doi.org/10.1111/crj.12425>.
12. Patel M. Targeting oxidative stress in central nervous system disorders. *Trends Pharmacol Sci*. 2016;37(9):768–78. <https://doi.org/10.1016/j.tips.2016.06.007>.
13. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol*. 2014;24(10):R453–62. <https://doi.org/10.1016/j.cub.2014.03.034>.
14. Zhang J, Wang X, Vikash V, et al. ROS and ROS-mediated cellular signaling. *Oxid Med Cell Longev*. 2016;2016:4350965. <https://doi.org/10.1155/2016/4350965>.
15. Chi L, Shan Y, Cui Z. N-Acetyl-L-Cysteine protects airway epithelial cells during respiratory syncytial virus infection against mucin synthesis, oxidative stress, and inflammatory response and inhibits hspα6 expression. *Anal Cell Pathol (Amst)*. 2022;2022:4846336. <https://doi.org/10.1155/2022/4846336>.
16. Ye S, Lowther S, Stambas J. Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3. *J Virol*. 2015;89(5):2672–83. <https://doi.org/10.1128/JVI.03529-14>.
17. Qian M, Tan HM, Yu N, Wang T, Zhang Q. Inactivated sendai virus induces ROS-dependent apoptosis and autophagy in human prostate cancer cells. *Biomed Environ Sci*. 2018;31(4):280–9. <https://doi.org/10.3967/bes2018.036>.
18. Li F, Li J, Wang PH, et al. SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. *Biochim Biophys Acta Mol Basis Dis*. 2021;1867(12): 166260. <https://doi.org/10.1016/j.bbdis.2021.166260>.
19. Michi AN, Yipp BG, Dufour A, Lopes F, Proud D. PGC-1α mediates a metabolic host defense response in human airway epithelium during rhinovirus infections. *Nat Commun*. 2021;12(1):3669. <https://doi.org/10.1038/s41467-021-23925-z>.
20. Cekerevac I, Turnic TN, Dragicin N, et al. Predicting severity and intra-hospital mortality in COVID-19: the place and role of oxidative stress. *Oxid Med Cell Longev*. 2021;2021:6615787. <https://doi.org/10.1155/2021/6615787>.
21. West AP, Brodsky IE, Rahner C, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. *Nature*. 2011;472(7344):476–80. <https://doi.org/10.1038/nature09973>.
22. Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox biology of respiratory viral infections. *Viruses*. 2018;10(8):392. <https://doi.org/10.3390/v10080392>.
23. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev*. 2007;87(1):245–313. <https://doi.org/10.1152/physrev.00044.2005>.
24. Vermot A, Petit-Härtlein I, Smith SME, et al. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology. *Antioxidants (Basel)*. 2021;10(6):890. <https://doi.org/10.3390/antiox10060890>.
25. Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. *Circ Res*. 2010;106(7):1253–64. <https://doi.org/10.1161/CIRCRESAHA.109.213116>.
26. Ambasta RK, Kumar P, Griendling KK, et al. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. *J Biol Chem*. 2004;279(44):45935–41. <https://doi.org/10.1074/jbc.M406486200>.
27. Kuroda J, Nakagawa K, Yamasaki T, et al. The superoxide-producing NAD(P)H oxidase Nox₄ in the nucleus of human vascular endothelial cells. *Genes Cells*. 2005;10(12):1139–51. <https://doi.org/10.1111/j.1365-2443.2005.00907.x>.
28. Muraro SP, De Souza GF, Gallo SW, et al. Respiratory syncytial virus induces the classical ROS-dependent NETosis through PAD-4 and necroptosis pathways activation. *Sci Rep*. 2018;8(1):14166. <https://doi.org/10.1038/s41598-018-32576-y>.
29. Segal AW. How neutrophils kill microbes. *Annu Rev Immunol*. 2005;23:197–223. <https://doi.org/10.1146/annurev.immunol.23.021704.115653>.
30. Leto TL, Geiszt M. Role of Nox family NADPH oxidases in host defense. *Antioxid Redox Signal*. 2006;8(9–10):1549–61. <https://doi.org/10.1089/ars.2006.8.1549>.
31. Trocme C, Deffert C, Cachat J, et al. Macrophage-specific NOX2 contributes to the development of lung emphysema through modulation of SIRT1/MMP-9 pathways. *J Pathol*. 2015;235(1):65–78. <https://doi.org/10.1002/path.4423>.
32. Jamaluddin M, Tian B, Boldogh I, Garofalo RP, Brasier AR. Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-phospho-Ser-276 RelA pathway required for cytokine expression. *J Virol*. 2009;83(20):10605–15. <https://doi.org/10.1128/JVI.01090-09>.
33. Indukuri H, Castro SM, Liao SM, et al. Ikkepsilon regulates viral-induced interferon regulatory factor-3 activation via a redox-sensitive pathway. *Virology*. 2006;353(1):155–65. <https://doi.org/10.1016/j.virol.2006.05.022>.
34. Fink K, Duval A, Martel A, Soucy-Faulkner A, Grandvaux N. Dual role of NOX2 in respiratory syncytial virus-and sendai virus-induced activation of NF-kappaB in airway epithelial cells. *J Immunol*. 2008;180(10):6911–22. <https://doi.org/10.4049/jimmunol.180.10.6911>.
35. Khan NA, Singla M, Samal S, Lodha R, Medigeshi GR. Respiratory syncytial virus-induced oxidative stress leads to an increase in labile zinc pools in lung epithelial cells. *Mosphere*. 2020;5(3):e00447–e520. <https://doi.org/10.1128/mSphere.00447-20>.
36. Cadenas S. Mitochondrial uncoupling, ROS generation and cardioprotection. *Biochim Biophys Acta Bioenerg*. 2018;1859(9):940–50. <https://doi.org/10.1016/j.bbmbio.2018.05.019>.
37. Andrieux P, Chevillard C, Cunha-Neto E, Nunes JPS. Mitochondria as a cellular hub in infection and inflammation. *Int J Mol Sci*. 2021;22(21):11338. <https://doi.org/10.3390/ijms222111338>.
38. Meuren LM, Prestes EB, Papa MP, et al. Infection of endothelial cells by dengue virus induces ros production by different sources affecting virus replication, cellular activation, death and vascular permeability. *Front Immunol*. 2022;13:810376. <https://doi.org/10.3389/fimmu.2022.810376>.
39. Cheng ML, Wu CH, Chien KY, et al. Enteroviral 2B interacts with VDAC3 to regulate reactive oxygen species generation that is essential to viral replication. *Viruses*. 2022;14(8):1717. <https://doi.org/10.3390/v14081717>.

40. Kelesidis T, Madhav S, Petcherski A, et al. The ApoA-I mimetic peptide 4F attenuates *in vitro* replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells. *Virulence*. 2021;12(1):2214–27. <https://doi.org/10.1080/21505594.2021.1964329>.
41. Hu M, Schulze KE, Ghildyal R, et al. Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production. *Elife*. 2019;8:e42448. <https://doi.org/10.7554/eLife.42448>.
42. Martínez I, García-Carpizo V, Guijarro T, et al. Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. *Virulence*. 2016;7(4):427–42. <https://doi.org/10.1080/21505594.2016.1144001>.
43. Hu M, Bogoyevitch MA, Jans DA. Subversion of host cell mitochondria by RSV to favor virus production is dependent on inhibition of mitochondrial complex I and ROS generation. *Cells*. 2019;8(11):1417. <https://doi.org/10.3390/cells8111417>.
44. Cervantes-Ortiz SL, Zamorano Cuervo N, Grandvaux N. Respiratory syncytial virus and cellular stress responses: impact on replication and physiopathology. *Viruses*. 2016;8(5):124. <https://doi.org/10.3390/v8050124>.
45. Brookes PS, Yoon Y, Botham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *Am J Physiol Cell Physiol*. 2004;287(4):C817–33. <https://doi.org/10.1152/ajpcell.00139.2004>.
46. Ren K, Lv Y, Zhuo Y, et al. Suppression of IRG-1 reduces inflammatory cell infiltration and lung injury in respiratory syncytial virus infection by reducing production of reactive oxygen species. *J Virol*. 2016;90(16):7313–22. <https://doi.org/10.1128/JVI.00563-16>.
47. Liu X, Wu XP, Zhu XL, Li T, Liu Y. IRG1 increases MHC class I level in macrophages through STAT-TAP1 axis depending on NADPH oxidase mediated reactive oxygen species. *Int Immunopharmacol*. 2017;48:76–83. <https://doi.org/10.1016/j.intimp.2017.04.012>.
48. Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature*. 2018;556(7699):113–7. <https://doi.org/10.1038/nature25986>.
49. Hosakote YM, Jantzi PD, Esham DL, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. *Am J Respir Crit Care Med*. 2011;183(11):1550–60. <https://doi.org/10.1164/rccm.201010-1755OC>.
50. Huang SH, Cao XJ, Liu W, Shi XY, Wei W. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. *J Pineal Res*. 2010;48(2):109–16. <https://doi.org/10.1111/j.1600-079X.2009.00733.x>.
51. Wang MM, Lu M, Zhang CL, et al. Oxidative stress modulates the expression of toll-like receptor 3 during respiratory syncytial virus infection in human lung epithelial A549 cells. *Mol Med Rep*. 2018;18(2):1867–77. <https://doi.org/10.3892/mmr.2018.9089>.
52. Hosakote YM, Liu T, Castro SM, Garofalo RP, Casola A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. *Am J Respir Cell Mol Biol*. 2009;41(3):348–57. <https://doi.org/10.1165/rcmb.2008-0330OC>.
53. Komaravelli N, Tian B, Ivanciu T, et al. Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2. *Free Radic Biol Med*. 2015;88(Pt B):391–403. <https://doi.org/10.1016/j.freeradbiomed.2015.05.043>.
54. de Souza GF, Muraro SP, Santos LD, et al. Macrophage migration inhibitory factor (MIF) controls cytokine release during respiratory syncytial virus infection in macrophages. *Inflamm Res*. 2019;68(6):481–91. <https://doi.org/10.1007/s00011-019-01233-z>.
55. Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. Nrf2, the master regulator of anti-oxidative responses. *Int J Mol Sci*. 2017;18(12):2772. <https://doi.org/10.3390/ijms18122772>.
56. Kang MI, Kobayashi A, Wakabayashi N, Kim SG, Yamamoto M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. *Proc Natl Acad Sci*. 2004;101(7):2046–51. <https://doi.org/10.1073/pnas.0308347100>.
57. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim Biophys Acta Mol Cell Res*. 2018;1865(5):721–33. <https://doi.org/10.1016/j.bbamcr.2018.02.010>.
58. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. *Med Res Rev*. 2012;32(4):687–726. <https://doi.org/10.1002/med.21257>.
59. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol*. 2007;47:89–116. <https://doi.org/10.1146/annurev.pharmtox.46.120604.141046>.
60. Komaravelli N, Ansar M, Garofalo RP, Casola A. Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein-ring finger protein 4 dependent pathway. *Free Radic Biol Med*. 2017;113:494–504. <https://doi.org/10.1016/j.freeradbiomed.2017.10.380>.
61. Mazarakis N, Higgins RA, Anderson J, et al. The effects of the dietary compound L-sulforaphane against respiratory pathogens. *Int J Antimicrob Agents*. 2021;58(6):106460. <https://doi.org/10.1016/j.ijantimicag.2021.106460>.
62. Haas de Mello A, Liu T, Garofalo RP, Casola A. Hydrogen sulfide donor GYY4137 rescues NRF2 activation in respiratory syncytial virus infection. *Antioxidants (Basel)*. 2022;11(7):1410. <https://doi.org/10.3390/antiox11071410>.
63. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell*. 2010;140(6):805–20. <https://doi.org/10.1016/j.cell.2010.01.022>.
64. Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. *Annu Rev Immunol*. 2023;41:301–16. <https://doi.org/10.1146/annurev-immunol-081022-021207>.
65. Zhao C, Zhao W. NLRP3 inflammasome—a key player in antiviral responses. *Front Immunol*. 2020;11:211. <https://doi.org/10.3389/fimmu.2020.00211>.
66. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. *Int J Mol Sci*. 2019;20(13):3328. <https://doi.org/10.3390/ijms20133328>.
67. Dominic A, Le NT, Takahashi M. Loop between NLRP3 inflammasome and reactive oxygen species. *Antioxid Redox Signal*. 2022;36(10–12):784–96. <https://doi.org/10.1089/ars.2020.8257>.
68. Groß CJ, Mishra R, Schneider KS, et al. K⁺ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. *Immunity*. 2016;45(4):761–73. <https://doi.org/10.1016/j.immuni.2016.08.010>.
69. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. *Front Physiol*. 2014;5:352. <https://doi.org/10.3389/fphys.2014.00352>.
70. Bedient L, Pokharel SM, Chiok KR, et al. Lytic cell death mechanisms in human respiratory syncytial virus-infected macrophages: roles of pyroptosis and necroptosis. *Viruses*. 2020;12(9):932. <https://doi.org/10.3390/v12090932>.
71. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. *Nature*. 2011;469(7329):221–5. <https://doi.org/10.1038/nature09663>.
72. Teng JF, Mei QB, Zhou XG, et al. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF- κ B/NLRP3/GSDMD signal axis in non-small cell lung cancer. *Cancers (Basel)*. 2020;12(1):193. <https://doi.org/10.3390/cancers12010193>.
73. Choudhury SM, Ma X, Abdullah SW, Zheng H. Activation and inhibition of the NLRP3 inflammasome by RNA viruses. *J Inflamm Res*. 2021;14:1145–63. <https://doi.org/10.2147/JIR.S295706>.
74. Han Y, Xu X, Tang C, et al. Reactive oxygen species promote tubular injury in diabetic nephropathy: the role of the mitochondrial rosnip-nlrp3 biological axis. *Redox Biol*. 2018;16:32–46. <https://doi.org/10.1016/j.redox.2018.02.013>.
75. Li Z, Liu T, Feng Y, et al. PPAR γ alleviates sepsis-induced liver injury by inhibiting hepatocyte pyroptosis via inhibition of the ROS/TXNIP/NLRP3 signaling pathway. *Oxid Med Cell Longev*. 2022;2022:1269747. <https://doi.org/10.1155/2022/1269747>.
76. Malinczak CA, Schuler CF, Duran AJ, et al. NLRP3-inflammasome inhibition during respiratory virus infection abrogates lung immunopathology and long-term airway disease development. *Viruses*. 2021;13(4):692. <https://doi.org/10.3390/v13040692>.
77. Chen YQ, Zhou Y, Wang QL, et al. Conciliatory anti-allergic decoction attenuates pyroptosis in RSV-infected asthmatic mice and lipopolysaccharide (LPS)-Induced 16HBE cells by inhibiting TLR3/NLRP3/NF- κ B/IRF3 signaling pathway. *J Immunol Res*. 2022;2022:1800401. <https://doi.org/10.1155/2022/1800401>.
78. Segovia J, Sabbah A, Mgbemena V, et al. TLR2/MyD88/NF- κ B pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC

- inflammasome during respiratory syncytial virus infection. *PLoS ONE*. 2012;7(1): e29695. <https://doi.org/10.1371/journal.pone.0029695>.
79. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006;124(4):783–801. <https://doi.org/10.1016/j.cell.2006.02.015>.
 80. Shen C, Zhang Z, Xie T, et al. Jinxin oral liquid inhibits human respiratory syncytial virus-induced excessive inflammation associated with blockade of the NLRP3/ASC/Caspase-1 pathway. *Biomed Pharmacother*. 2018;103:1376–83. <https://doi.org/10.1016/j.biopha.2018.04.174>.
 81. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. *Nat Rev Microbiol*. 2009;7(2):99–109. <https://doi.org/10.1038/nrmicro2070>.
 82. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. *Nature*. 2015;517(7534):311–20. <https://doi.org/10.1038/nature14191>.
 83. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. *Nat Rev Mol Cell Biol*. 2021;22(4):266–82. <https://doi.org/10.1038/s41580-020-00324-8>.
 84. Newton K, Dixit VM, Kayagaki N. Dying cells fan the flames of inflammation. *Science*. 2021;374(6571):1076–80. <https://doi.org/10.1126/science.abi5934>.
 85. Puri G, Naura AS. Implication of mitochondrial ROS-NLRP3 inflammasome axis during two-hit mediated acute lung injury in mice. *Free Radic Res*. 2022;56(1):1–16. <https://doi.org/10.1080/10715762.2021.2023740>.
 86. Shen C, Zhang Z, Xie T, et al. Rhein suppresses lung inflammatory injury induced by human respiratory syncytial virus through inhibiting NLRP3 inflammasome activation via NF- κ B pathway in mice. *Front Pharmacol*. 2020;10:1600. <https://doi.org/10.3389/fphar.2019.01600>.
 87. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303(5663):1532–5. <https://doi.org/10.1126/science.1092385>.
 88. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol*. 2007;176(2):231–41. <https://doi.org/10.1083/jcb.200606027>.
 89. Parker H, Dragunow M, Hampton MB, Kettle AJ, Winterbourn CC. Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus. *J Leukoc Biol*. 2012;92(4):841–9. <https://doi.org/10.1189/jlb.1211601>.
 90. Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutiérrez L, García-Orozco A, Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular traps and its implications in inflammation: an overview. *Front Immunol*. 2017;8:81. <https://doi.org/10.3389/fimmu.2017.00081>.
 91. Yoo DG, Winn M, Pang L, et al. Release of cystic fibrosis airway inflammatory markers from *Pseudomonas aeruginosa*-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation. *J Immunol*. 2014;192(10):4728–38. <https://doi.org/10.4049/jimmunol.1301589>.
 92. Pilszczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to *Staphylococcus aureus*. *J Immunol*. 2010;185(12):7413–25. <https://doi.org/10.4049/jimmunol.1000675>.
 93. Al-Khafaji AB, Tohme S, Yazdani HO, Miller D, Huang H, Tsung A. Super-oxide induces neutrophil extracellular trap formation in a TLR-4 and NOX-dependent mechanism. *Mol Med*. 2016;22:621–31. <https://doi.org/10.2119/molmed.2016.00054>.
 94. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. *J Exp Med*. 2010;207(9):1853–62. <https://doi.org/10.1084/jem.20100239>.
 95. Lewis HD, Liddle J, Coote JE, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. *Nat Chem Biol*. 2015;11(3):189–91. <https://doi.org/10.1038/nchembio.1735>.
 96. Yousefi S, Mihalache C, Kozłowski E, Schmid I, Simon HU. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ*. 2009;16(11):1438–44. <https://doi.org/10.1038/cdd.2009.96>.
 97. Simpson J, Loh Z, Ullah MA, et al. Respiratory syncytial virus infection promotes necroptosis and HMGB1 release by airway epithelial cells. *Am J Respir Crit Care Med*. 2020;201(11):1358–71. <https://doi.org/10.1164/rccm.201906-1149OC>.
 98. Herbert JA, Deng Y, Hardelid P, et al. β 2-integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection. *Eur Respir J*. 2020;56(2):1902216. <https://doi.org/10.1183/13993003.02216-2019>.
 99. Juliana A, Zonneveld R, Plötz FB, van Meurs M, Wilschut J. Neutrophil-endothelial interactions in respiratory syncytial virus bronchiolitis: an understudied aspect with a potential for prediction of severity of disease. *J Clin Virol*. 2020;123: 104258. <https://doi.org/10.1016/j.jcv.2019.104258>.
 100. Sebina I, Rashid RB, Sikder MAA, et al. IFN- λ diminishes the severity of viral bronchiolitis in neonatal mice by limiting NADPH oxidase-induced PAD4-independent NETosis. *J Immunol*. 2022;208(12):2806–16. <https://doi.org/10.4049/jimmunol.2100876>.
 101. Funchal GA, Jaeger N, Czepielewski RS, et al. Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils. *PLoS ONE*. 2015;10(4):e0124082. <https://doi.org/10.1371/journal.pone.0124082>.
 102. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol*. 2010;191(3):677–91. <https://doi.org/10.1083/jcb.201006052>.
 103. Souza PSS, Barbosa LV, Diniz LFA, et al. Neutrophil extracellular traps possess anti-human respiratory syncytial virus activity: possible interaction with the viral F protein. *Virus Res*. 2018;251:68–77. <https://doi.org/10.1016/j.virusres.2018.04.001>.
 104. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. *J Immunol*. 2012;189(6):2689–95. <https://doi.org/10.4049/jimmunol.1201719>.
 105. Yildiz C, Palaniyar N, Otulakowski G, et al. Mechanical ventilation induces neutrophil extracellular trap formation. *Anesthesiology*. 2015;122(4):864–75. <https://doi.org/10.1097/ALN.0000000000000605>.
 106. Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. *Lancet Respir Med*. 2021;9(8):873–84. [https://doi.org/10.1016/S2213-2600\(20\)30504-X](https://doi.org/10.1016/S2213-2600(20)30504-X).
 107. Cortjens B, de Boer OJ, de Jong R, et al. Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. *J Pathol*. 2016;238(3):401–11. <https://doi.org/10.1002/path.4660>.
 108. Cortjens B, de Jong R, Bonsing JG, van Woensel JBM, Antonis AFG, Bem RA. Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection. *Thorax*. 2018;73(6):578–80. <https://doi.org/10.1136/thoraxjnl-2017-210289>.
 109. Lefrançois E, Mallavia B, Zhuo H, Calfee CS, Looney MR. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. *JCI Insight*. 2018;3(3):e98178. <https://doi.org/10.1172/jci.insight.98178>.
 110. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. *J Exp Med*. 2020;217(6): e20200652. <https://doi.org/10.1084/jem.20200652>.
 111. Arcanjo A, Logullo J, Menezes CCB, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). *Sci Rep*. 2020;10(1):19630. <https://doi.org/10.1038/s41598-020-76781-0>.
 112. Delaveris CS, Wilk AJ, Riley NM, et al. Synthetic Siglec-9 agonists inhibit neutrophil activation associated with COVID-19. *ACS Cent Sci*. 2021;7(4):650–7. <https://doi.org/10.1021/acscentsci.0c01669>.
 113. Besteman SB, Callaghan A, Hennus MP, Westerlaken GHA, Meeyaard L, Bont LL. Signal inhibitory receptor on leukocytes (SIRL)-1 and leukocyte-associated immunoglobulin-like receptor (LAIR)-1 regulate neutrophil function in infants. *Clin Immunol*. 2020;211: 108324. <https://doi.org/10.1016/j.clim.2019.108324>.
 114. Gaboriaud C, Lorvellec M, Rossi V, Dumestre-Pérard C, Thielens NM. Complement system and alarmin HMGB1 crosstalk: For better or worse. *Front Immunol*. 2022;13:869720. <https://doi.org/10.3389/fimmu.2022.869720>.
 115. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus ERYTHEMATOSUS: Its role in cutaneous lesions development. *Autoimmun Rev*. 2010;9(10):661–5. <https://doi.org/10.1016/j.autrev.2010.05.015>.
 116. Lu H, Zhu M, Qu L, Shao H, Zhang R, Li Y. Oncogenic role of HMGB1 as an alarming in robust prediction of immunotherapy response in

- colorectal cancer. *Cancers (Basel)*. 2022;14(19):4875. <https://doi.org/10.3390/cancers14194875>.
117. Hua S, Ma M, Fei X, Zhang Y, Gong F, Fang M. Glycyrrhizin attenuates hepatic ischemia-reperfusion injury by suppressing HMGB1-dependent GSDMD-mediated kupffer cells pyroptosis. *Int Immunopharmacol*. 2019;68:145–55. <https://doi.org/10.1016/j.intimp.2019.01.002>.
 118. Wang Y, Zhong J, Zhang X, et al. The role of HMGB1 in the pathogenesis of Type 2 diabetes. *J Diabetes Res*. 2016;2016:2543268. <https://doi.org/10.1155/2016/2543268>.
 119. Kim YH, Kwak MS, Lee B, et al. Secretory autophagy machinery and vesicular trafficking are involved in HMGB1 secretion. *Autophagy*. 2021;17(9):2345–62. <https://doi.org/10.1080/15548627.2020.1826690>.
 120. Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. *Nature*. 2012;488(7413):670–4. <https://doi.org/10.1038/nature11290>.
 121. Hosakote YM, Brasier AR, Casola A, Garofalo RP, Kurosky A. Respiratory syncytial virus infection triggers epithelial HMGB1 release as a damage-associated molecular pattern promoting a monocytic inflammatory response. *J Virol*. 2016;90(21):9618–31. <https://doi.org/10.1128/JVI.01279-16>.
 122. Manti S, Harford TJ, Salpietro C, Rezaee F, Piedimonte G. Induction of high-mobility group Box-1 *in vitro* and *in vivo* by respiratory syncytial virus. *Pediatr Res*. 2018;83(5):1049–56. <https://doi.org/10.1038/pr.2018.6>.
 123. Niu M, Jiang Z, Xin X, et al. Effect of HMGB1 on monocytic immune function in respiratory syncytial virus bronchiolitis. *Exp Ther Med*. 2021;21(1):75. <https://doi.org/10.3892/etm.2020.9507>.
 124. Chen S, Yu G, Xie J, et al. High-mobility group box-1 protein from CC10+ club cells promotes type 2 response in the later stage of respiratory syncytial virus infection. *Am J Physiol Lung Cell Mol Physiol*. 2019;316(1):L280–90. <https://doi.org/10.1152/ajplung.00552.2017>.
 125. Passos FRS, Heimfarth L, Monteiro BS, et al. Oxidative stress and inflammatory markers in patients with COVID-19: potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. *Int Immunopharmacol*. 2022;104: 108502. <https://doi.org/10.1016/j.intimp.2021.108502>.
 126. Cui T, Zhang W, Li S, et al. Oxidative stress-induced hmgb1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. *J Invest Dermatol*. 2019;139(10):2174–2184.e4. <https://doi.org/10.1016/j.jid.2019.03.1148>.
 127. Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. *Front Physiol*. 2015;6:93. <https://doi.org/10.3389/fphys.2015.00093>.
 128. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. *Antioxid Redox Signal*. 2011;14(7):1315–35. <https://doi.org/10.1089/ars.2010.3356>.
 129. Simpson J, Spann KM, Phipps S. MLKL regulates rapid cell death-independent HMGB1 release in RSV infected airway epithelial cells. *Front Cell Dev Biol*. 2022;10:890389. <https://doi.org/10.3389/fcell.2022.890389>.
 130. Rayavara K, Kurosky A, Stafford SJ, et al. Proinflammatory effects of respiratory syncytial virus-induced epithelial HMGB1 on human innate immune cell activation. *J Immunol*. 2018;201(9):2753–66. <https://doi.org/10.4049/jimmunol.1800558>.
 131. Rossi GA, Ballarini S, Salvati P, Sacco O, Colin AA. Alarmins and innate lymphoid cells 2 activation: A common pathogenetic link connecting respiratory syncytial virus bronchiolitis and later wheezing/asthma? *Pediatr Allergy Immunol*. 2022;33(6): e13803. <https://doi.org/10.1111/pai.13803>.
 132. Norlander AE, Peebles RS Jr. Innate type 2 responses to respiratory syncytial virus infection. *Viruses*. 2020;12(5):521. <https://doi.org/10.3390/v12050521>.
 133. Zhao Y, Li R. HMGB1 is a promising therapeutic target for asthma. *Cytokine*. 2023;165: 156171. <https://doi.org/10.1016/j.cyto.2023.156171>.
 134. Arikatt J, Ullah MA, Short KR, et al. RAGE deficiency predisposes mice to virus-induced paucigranulocytic asthma. *Elife*. 2017;6:e21199. <https://doi.org/10.7554/eLife.21199>.
 135. Moore JM, Correa R, Rosenberg SM, Hastings PJ. Persistent damaged bases in DNA allow mutagenic break repair in *Escherichia coli*. *PLoS Genet*. 2017;13(7):e1006733. <https://doi.org/10.1371/journal.pgen.1006733>.
 136. Bauer M, Goldstein M, Christmann M, Becker H, Heylmann D, Kaina B. Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. *Proc Natl Acad Sci*. 2011;108(52):21105–10. <https://doi.org/10.1073/pnas.1111919109>.
 137. Ui A, Chiba N, Yasui A. Relationship among DNA double-strand break (DSB), DSB repair, and transcription prevents genome instability and cancer. *Cancer Sci*. 2020;111(5):1443–51. <https://doi.org/10.1111/cas.14404>.
 138. Schubert I. Boon and bane of DNA double-strand breaks. *Int J Mol Sci*. 2021;22(10):5171. <https://doi.org/10.3390/ijms22105171>.
 139. Puc J, Aggarwal AK, Rosenfeld MG. Physiological functions of programmed DNA breaks in signal-induced transcription. *Nat Rev Mol Cell Biol*. 2017;18(8):471–6. <https://doi.org/10.1038/nrm.2017.43>.
 140. Hong Y, Li L, Luan G, Drlica K, Zhao X. Contribution of reactive oxygen species to thymineless death in *Escherichia coli*. *Nat Microbiol*. 2017;2(12):1667–75. <https://doi.org/10.1038/s41564-017-0037-y>.
 141. Rodier F, Coppé JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. *Nat Cell Biol*. 2009;11(8):973–9. <https://doi.org/10.1038/ncb1909>.
 142. Fang L, Choudhary S, Tian B, et al. Ataxia telangiectasia mutated kinase mediates NF- κ B serine 276 phosphorylation and interferon expression via the IRF7-RIG-I amplification loop in paramyxovirus infection. *J Virol*. 2015;89(5):2628–42. <https://doi.org/10.1128/JVI.02458-14>.
 143. Dumont P. Increasing the complexity of respiratory syncytial virus infection: reactive oxygen species, DNA damage, and premature senescence. *Virulence*. 2016;7(4):372–5. <https://doi.org/10.1080/21505594.2016.1162370>.
 144. Kelley WJ, Zemans RL, Goldstein DR. Cellular senescence: Friend or foe to respiratory viral infections? *Eur Respir J*. 2020;56(6):2002708. <https://doi.org/10.1183/13993003.02708-2020>.
 145. Dizdaroğlu M, Coskun E, Jaruga P. Repair of oxidatively induced DNA damage by DNA glycosylases: mechanisms of action, substrate specificities and excision kinetics. *Mutat Res Rev Mutat Res*. 2017;771:99–127. <https://doi.org/10.1016/j.mrrev.2017.02.001>.
 146. Zheng X, Wang K, Pan L, et al. Innate immune responses to RSV infection facilitated by OGG1, an enzyme repairing oxidatively modified DNA base lesions. *J Innate Immun*. 2022;14(6):593–614. <https://doi.org/10.1159/000524186>.
 147. Stout SL, Wyatt TA, Adams JJ, Sisson JH. Nitric oxide-dependent cilia regulatory enzyme localization in bovine bronchial epithelial cells. *J Histochem Cytochem*. 2007;55(5):433–42. <https://doi.org/10.1369/jhc.6A7089.2007>.
 148. Jackson CL, Lucas JS, Walker WT, Owen H, Premadeva I, Lackie PM. Neuronal NOS localises to human airway cilia. *Nitric Oxide*. 2015;44:3–7. <https://doi.org/10.1016/j.niox.2014.11.003>.
 149. Blackburn K, Bustamante-Marin X, Yin W, Goshe MB, Ostrowski LE. Quantitative proteomic analysis of human airway cilia identifies previously uncharacterized proteins of high abundance. *J Proteome Res*. 2017;16(4):1579–92. <https://doi.org/10.1021/acs.jproteome.6b00972>.
 150. Price ME, Sisson JH. Redox regulation of motile cilia in airway disease. *Redox Biol*. 2019;27: 101146. <https://doi.org/10.1016/j.redox.2019.101146>.
 151. Ostrowski LE, Blackburn K, Radde KM, et al. A proteomic analysis of human cilia: identification of novel components. *Mol Cell Proteom*. 2002;1(6):451–65. <https://doi.org/10.1074/mcp.m200037-mcp200>.
 152. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. *J Virol*. 2002;76(11):5654–66. <https://doi.org/10.1128/jvi.76.11.5654-5666.2002>.
 153. Smith CM, Kulkarni H, Radhakrishnan P, et al. Ciliary dyskinesia is an early feature of respiratory syncytial virus infection. *Eur Respir J*. 2014;43(2):485–96. <https://doi.org/10.1183/09031936.00205312>.
 154. Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. *PLoS Pathog*. 2015;11(12):e1005318. <https://doi.org/10.1371/journal.ppat.1005318>.
 155. Anderson CS, Chirkova T, Slaunwhite CG, et al. CX3CR1 engagement by respiratory syncytial virus leads to induction of nucleolin and dysregulation of cilia-related genes. *J Virol*. 2021;95(11):e00095–21. <https://doi.org/10.1128/JVI.00095-21>.
 156. Nicolas de Lamballerie C, Pizzorno A, Dubois J, et al. Characterization of cellular transcriptomic signatures induced by different

- respiratory viruses in human reconstituted airway epithelia. *Sci Rep*. 2019;9(1):11493. <https://doi.org/10.1038/s41598-019-48013-7>.
157. Koch CM, Prigge AD, Setar L, et al. Cilia-related gene signature in the nasal mucosa correlates with disease severity and outcomes in critical respiratory syncytial virus bronchiolitis. *Front Immunol*. 2022;13:924792. <https://doi.org/10.3389/fimmu.2022.924792>.
 158. Jumat MR, Yan Y, Ravi LI, et al. Morphogenesis of respiratory syncytial virus in human primary nasal ciliated epithelial cells occurs at surface membrane microdomains that are distinct from cilia. *Virology*. 2015;484:395–411. <https://doi.org/10.1016/j.virol.2015.05.014>.
 159. Essaidi-Laziosi M, Brito F, Benaoudia S, et al. Propagation of respiratory viruses in human airway epithelia reveals persistent virus-specific signatures. *J Allergy Clin Immunol*. 2018;141(6):2074–84. <https://doi.org/10.1016/j.jaci.2017.07.018>.
 160. Geiser J, Boivin G, Huang S, et al. RSV and HMPV infections in 3D tissue cultures: mechanisms involved in virus–host and virus–virus interactions. *Viruses*. 2021;13(1):139. <https://doi.org/10.3390/v13010139>.
 161. Mata M, Sarrion I, Armengot M, et al. Respiratory syncytial virus inhibits ciliogenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. *PLoS ONE*. 2012;7(10): e48037. <https://doi.org/10.1371/journal.pone.0048037>.
 162. Mata M, Martinez I, Melero JA, Tenor H, Cortijo J. Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells. *PLoS ONE*. 2013;8(7):e69670. <https://doi.org/10.1371/journal.pone.0069670>.
 163. Smallcombe CC, Harford TJ, Linfield DT, et al. Titanium dioxide nanoparticles exaggerate respiratory syncytial virus-induced airway epithelial barrier dysfunction. *Am J Physiol Lung Cell Mol Physiol*. 2020;319(3):L481–96. <https://doi.org/10.1152/ajplung.00104.2020>.
 164. Checconi P, De Angelis M, Marcocci ME, et al. Redox-modulating agents in the treatment of viral infections. *Int J Mol Sci*. 2020;21(11):4084. <https://doi.org/10.3390/ijms21114084>.
 165. Li K, Xu Y, Yue W. Anti-viral activity of jatrophone against RSV-induced respiratory infection via increase in interferon- γ generating dendritic cells. *Environ Toxicol*. 2020;35(8):888–94. <https://doi.org/10.1002/tox.22925>.
 166. Lee SR. Critical role of zinc as either an antioxidant or a prooxidant in cellular systems. *Oxid Med Cell Longev*. 2018;2018:9156285. <https://doi.org/10.1155/2018/9156285>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

